Acquiring Company
Azenta
Acquired Company
SynPlexity
BurlingtonBiotechnologyHealth CareLife ScienceManufacturingBiotechnologyHealth CareDescription
Azenta, Inc. announced strategic investments to expand its GENEWIZ gene synthesis business, including an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc. The SynPlexity acquisition adds pooled gene assembly technology that provides thousands of full-length gene variants in a single library. The investments are aimed at accelerating growth in synthetic biology, protein engineering and AI-enabled drug discovery.
Who to call at Azenta, and when
When Azenta changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Azenta raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Azenta, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Azenta. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Azenta makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired SynPlexity?
SynPlexity was acquired by Azenta, based in Burlington. The deal was reported on October 30, 2026. Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta is publicly traded (AZTA) and operates in Biotechnology.
When did Azenta acquire SynPlexity?
Azenta's acquisition of SynPlexity was reported on October 30, 2026. Azenta, Inc. announced strategic investments to expand its GENEWIZ gene synthesis business, including an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does SynPlexity do?
SynPlexity is a DNA assembly technology company providing products and services centered on large, multiplexed libraries for functional screening, drug discovery, therapeutics and other applications. It is privately held, operating in Manufacturing.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.